CL King Initiates Coverage On Integra Lifesciences With Buy Rating, Announces Price Target of $50
CL King Initiates Coverage On Integra Lifesciences With Buy Rating, Announces Price Target of $50
CL King以買入評級啓動對Integra Lifesciences的報道，宣佈目標股價爲50美元
CL King analyst Kristen Stewart initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Buy rating and announces Price Target of $50.
CL King分析師克里斯汀·斯圖爾特以買入評級開始報道Integra Lifesciences（納斯達克股票代碼：IART），並宣佈目標股價爲50美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。